Ergomed consolidates North American growth

Contract pharma research provider Ergomed (LON: ERGO) is in the top forty best AIM performers over five years with a 635% increase in the share price and it is not far from quadrupling over the past year. That means that the shares have a heady rating, but the growing market and potential for earnings enhancing acquisitions make it appear warranted.

Ergomed decided to concentrate on third-party services rather than co-development more than two years ago. Last year, two major acquisitions were made in the important North American market and management would like to further increase scale in...

Previous articleTemple Bar Investment Trust presents at the UK Investor Magazine Virtual Conference 23rd March
Next articleThe London Stock Exchange Group presents at the UK Investor Magazine Virtual Conference
Andrew Hore is the publisher of AIM Journal, which is an online monthly publication covering the Alternative Investment Market.